 |
53 Diseases |  |
490 Trials |
|
490 Trials |  |
8927 News |  |
| «12...9899100101102103104105106107108...123124» |
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: Indeed. mOS 10.7 in SHARP Vs 11.2 in IMbrave50 Would be interesting to check what's the proportion of actual HCC patients that fill the criteria of SHARP, Lenvatinib and IMBrave. (Twitter) - Aug 4, 2020
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Early Change in the Plasma Levels of Circulating Soluble Immune Checkpoint Proteins in Patients with Unresectable Hepatocellular Carcinoma Treated by Lenvatinib or Transcatheter Arterial Chemoembolization. (Pubmed Central) - Jul 30, 2020
Our results suggest that there are some limited differences in immunomodulatory effects between anti-angiogenic agents and TACE. Further studies from multicenters may help to identify an effective combination therapy.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Assessment of the efficacy and safety of lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer in real-life practice in Russia (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2658;
Legal entity responsible for the study: The authors. Funding: Eisai LLC Russia.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
[VIRTUAL] Final analysis of RIFTOS MKI, a global, non-interventional study assessing the use of multikinase inhibitors (MKIs) for the treatment of patients with asymptomatic radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2653;
P=N/A
Funding: Bayer. Clinical trial identification: NCT02303444.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Pembrolizumab salvage add-on therapy in patients with radioiodine-refractory (RAIR), progressive differentiated thyroid cancer (DTC) progressing on lenvatinib: Results of a multicenter phase II International Thyroid Oncology Group Trial (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2652;
P2
Funding: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc Eisai, Inc International Thyroid Oncology Group (ITOG). Clinical trial identification: NCT02973997.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] The lenvatinib/pembrolizumab combination induces long lasting and complete responses in patients with metastatic anaplastic or poorly differentiated thyroid carcinoma: Results from a retrospective study and first results from the prospective phase II ATLEP trial (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2650;
Funding: University of Freiburg. Clinical trial identification: 2017-004570-3.
- [VIRTUAL] A multicenter, open-label, randomized phase II study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with relapsed or refractory osteosarcoma (OLIE; ITCC-082) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2423;
P2
Funding: Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Clinical trial identification: NCT04154189.
- Yondelis (trabectedin) / Otsuka, PharmaMar, Valeo Pharma, doxorubicin hydrochloride / Generic mfg.
[VIRTUAL] The promising role of the extracellular matrix in the activity of trabectedin in soft tissue sarcoma: A prospective study on a UPS and L-sarcoma patient-derived primary culture case series using 3D and zebrafish models (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2416;
Second-line therapy may include trabectedin, eribulin, ifosfamide, gemcitabine and dacarbazine with no optimized standard sequential therapy...Combining our STS translational model based on 3D patient-derived primary cultures system and zebrafish we performed genomic-, pharmacological (testing ifosfamide, epirubicin, ifosfamide and epirubicin, doxorubicin, trabectedin, eribulin, dacarbazine and lenvatinib) proteomic- and in silico analysis...Legal entity responsible for the study: Toni Ibrahim. Funding: Has not received any funding.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] Real-world data on cabozantinib in advanced osteosarcoma and Ewing sarcoma - A study of the Hellenic Group of Sarcoma and Rare Cancers (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2401;
Angiogenesis and MET signaling have been shown to play an important role in these neoplasm and anti-angiogenic drugs (sorafenib, regorafenib, lenvatinib and cabozantinib have been tested in phase II trials in bone sarcomas...Previous lines of treatment included mainly ifosfamide/etoposide and gemcitabine/docetaxel...Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Phase III LEAP-006 safety run-in (Part 1): 1L pembrolizumab (Pembro) + chemotherapy (Chemo) with lenvatinib (Len) for metastatic NSCLC (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2093;
P3
and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Clinical trial identification: NCT03829319.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] LEAP-012 trial in progress: Pembrolizumab plus lenvatinib and transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1823;
P3
Funding: Merck Sharp & Dohme Corp. Clinical trial identification: NCT04246177.
- Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS
[VIRTUAL] Response rate to immune-checkpoint inhibitors in patients with advanced hepatocellular carcinoma: A systematic review with quantitative data analysis (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1812;
Nivolumab with ipilimumab provided higher OS and ORR in sorafenib progressors as compared to 2L SoC regorafenib...Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] PD1midKLRG1+Tbethigh effector memory T in the peripheral blood correlates with tumor response to combined therapy with lenvatinib and anti-PD-1 antibodies in unresectable hepatocellular carcinoma (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1808;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Effects of combination therapy using lenvatinib and anti-pd-1 antibody on liver function in patients with advanced hepatocellar carcinoma (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1796;
Legal entity responsible for the study: The authors. Funding: Has not received any funding.
- Opdivo (nivolumab) / Ono Pharma, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Safety analysis of the run-in phase (1st and 2nd cohort) of the IMMUNIB trial (AIO-HEP-0218/ass) - An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with nivolumab in combination with lenvatinib in advanced stage HCC (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1795;
P2
KGaA. Clinical trial identification: NCT03841201; EudraCT: 2018-001480-23.
- Lenvima (lenvatinib) / Eisai, Merck (MSD), CS1003 / CStone Pharma
[VIRTUAL] A phase Ib study of the PD-1 antagonist CS1003 plus lenvatinib (LEN) in Chinese patients (pts) with the first-line (1L) unresectable hepatocellular carcinoma (uHCC) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1794;
P1a/1b
Funding: CStone Pharmaceuticals (Su Zhou) Co., Ltd. Clinical trial identification: NCT03809767.
- Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1780;
P1b/2, P3
Funding: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Clinical trial identification: NCT04199104.
- BI 836880 / Boehringer Ingelheim, BI 754091 / Boehringer Ingelheim
[VIRTUAL] Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1619;
P1
Funding: Boehringer Ingelheim. Clinical trial identification: NCT03468426.
- ||| everolimus / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: "I was recently chairing a study comparing two dose levels of lenvatinib with everolimus, particularly for those patients with MTOR mutations....that's a great therapeutic space for lenvatinib with everolimus." @montypal @jgong15 (Twitter) - Jul 23, 2020
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Monotherapy, Metastases: Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) (clinicaltrials.gov) - Jul 21, 2020
P2, N=400, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Clinical trial identification: NCT03468426. Not yet recruiting --> Recruiting
- Keytruda (pembrolizumab) / Merck (MSD), everolimus / Generic mfg., Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Correlative serum biomarker analyses: Lenvatinib (LEN) plus pembrolizumab (PEMBRO) in a phase Ib/II trial in advanced renal cell carcinoma (RCC) (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_980;
P1b/2, P3
Funding: Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Clinical trial identification: NCT02501096.
- [VIRTUAL] Phase II trial of lenvatinib (LEN) + pembrolizumab (PEMBRO) for progressive disease after PD-1/PD-L1 immune checkpoint inhibitor (ICI) in metastatic clear cell (mcc) renal cell carcinoma (RCC): Results by independent imaging review and subgroup analyses (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_971;
P1b/2
PEMBRO + axitinib is approved as first-line therapy for advanced RCC...Results For the 104 pts enrolled, median duration of follow-up for OS was 12.3 months, 65% of pts had prior anti-PD-1/PD-L1 and anti-VEGF therapy in combination or sequentially, and 37% of pts had prior nivolumab + ipilimumab...Funding: Eisai Inc., Woodcliff Lake, NJ, USA, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Clinical trial identification: NCT02501096.
- Tuoyi (toripalimab) / Shanghai Junshi Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
[VIRTUAL] Anti-PD1 antibody toripalimab, lenvatinib and gemox chemotherapy as first-line treatment of advanced and unresectable intrahepatic cholangiocarcinoma: A phase II clinical trial (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_399;
P2
Funding: Has not received any funding. Clinical trial identification: NCT03951597.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib for thymic carcinomas. (Pubmed Central) - Jul 21, 2020
Clinical trial identification: NCT03951597. No abstract available
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, P2 data, Clinical Trial,Phase II, Journal: Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial. (Pubmed Central) - Jul 21, 2020
The activity and safety of lenvatinib in patients with advanced or metastatic thymic carcinoma was confirmed. These results suggest that lenvatinib could become a standard treatment option for patients with previously treated advanced or metastatic thymic carcinoma.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Lenvatinib-Induced Tumor-Related Hemorrhage in Patients With Unresectable Hepatocellular Carcinoma. (Pubmed Central) - Jul 19, 2020
These results suggest that lenvatinib could become a standard treatment option for patients with previously treated advanced or metastatic thymic carcinoma. No abstract available
- Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] OPTIMIZING SEQUENTIAL SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELULLAR CARCINOMA: A DECISION ANALYSIS (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_5014;
Single-agent, first-line Lenvatinib followed by Nivolumab or Pembrolizumab were identified as optimal sequential strategies for advanced HCC. These estimates should be considered for future clinical trials.
- Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] OPTIMIZING SEQUENTIAL SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELULLAR CARCINOMA: A DECISION ANALYSIS (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_3038;
Single-agent, first-line Lenvatinib followed by Nivolumab or Pembrolizumab were identified as optimal sequential strategies for advanced HCC. These estimates should be considered for future clinical trials.
- Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] OPTIMIZING SEQUENTIAL SYSTEMIC THERAPIES FOR ADVANCED HEPATOCELULLAR CARCINOMA: A DECISION ANALYSIS (Poster Exhibition) - Jul 19, 2020 - Abstract #UEGW2020UEGW_1054;
Single-agent, first-line Lenvatinib followed by Nivolumab or Pembrolizumab were identified as optimal sequential strategies for advanced HCC. These estimates should be considered for future clinical trials.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. (Pubmed Central) - Jul 18, 2020
A baseline albumin level >3.4g/dL or ALBI score less than -2.171 were significantly associated with achieving 4W-RDI ≥70%. In conclusion, 4W-RDI of lenvatinib therapy is associated with favorable radiological response and longer OS.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Retrospective data, Journal, Adverse events: Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study. (Pubmed Central) - Jul 17, 2020
We concluded that the appearance of hypertension has potential as an early surrogate marker to predict improved prognosis. Moreover, careful management to avoid discontinuation of treatment leads to longer survival in patients receiving LEN.
- | Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Journal, HEOR, Real-World Evidence: Potential use of lenvatinib for patients with unresectable hepatocellular carcinoma including after treatment with sorafenib: Real-world evidence and in vitro assessment via protein phosphorylation array. (Pubmed Central) - Jul 15, 2020
This suggests that LEN is active and safe as a second/third-line treatment for unresectable HCC. LEN seems more effective for patients with HCC with better hepatic reserve functions or before MTA-resistance is acquired because of the partial cross-resistance to SOR.
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open: Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) (clinicaltrials.gov) - Jul 14, 2020
P2, N=600, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
LEN seems more effective for patients with HCC with better hepatic reserve functions or before MTA-resistance is acquired because of the partial cross-resistance to SOR. Active, not recruiting --> Recruiting
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Metastases: Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC) (clinicaltrials.gov) - Jul 14, 2020
P1, N=15, Recruiting, Sponsor: Yousef Zakharia
Active, not recruiting --> Recruiting Suspended --> Recruiting
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment closed, Trial primary completion date, Metastases: LTHAIC: HAIC Plus Lenvatinib and Toripalimab for Advanced HCC (clinicaltrials.gov) - Jul 13, 2020
P2, N=35, Active, not recruiting, Sponsor: Shi Ming
Suspended --> Recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2020 --> Sep 2020
- ||||| Imfinzi (durvalumab) / AstraZeneca, BMS, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: For alk/egfr agree. Can’t paint all tkis with same brush, given safety of combio with braf, vegf tkis etc (acitinib, lenvatinib). This data does impact thoughts of consolidation durva in egfr/alk pos stage 3? Or, on first treatment of egfr/alk pos if recurs on durvalumab? (Twitter) - Jul 13, 2020
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment change, Trial completion date, Combination therapy, Metastases: A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease (clinicaltrials.gov) - Jul 13, 2020
P2, N=41, Active, not recruiting, Sponsor: Eisai Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2020 --> Sep 2020 N=31 --> 41 | Trial completion date: Mar 2020 --> Feb 2021
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment status: A Study of Overall Survival in Participants With Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Jul 13, 2020
P=N/A, N=500, Enrolling by invitation, Sponsor: Eisai Co., Ltd.
N=31 --> 41 | Trial completion date: Mar 2020 --> Feb 2021 Recruiting --> Enrolling by invitation
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, Heterogeneity: Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis. (Pubmed Central) - Jul 11, 2020
The CT enhancement pattern of HCC may predict response to lenvatinib. OR seems to occur more frequently in HCC with oncologically aggressive features and may contribute to prolonged survival through a prolonged progression-free interval, even in an oncologically poor-risk group of patients.
- | infigratinib (BGJ398) / BridgeBio, Pfizer, Lenvima (lenvatinib) / Eisai, Merck (MSD), Nexavar (sorafenib) / Bayer, Amgen
Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO Biomarker: Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma. (Pubmed Central) - Jul 11, 2020
Inhibition of vascular endothelial growth factor receptor and FGFR augmented the efficacy of anti-PD-1 antibodies. Combined lenvatinib/anti-PD-1 treatment appears to exert antitumor activity by synergistically modulating effector T cell function in the TME and by mutually regulating tumor vessel normalization.
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Pathological Complete Response in Conversion Hepatectomy Induced by Lenvatinib for Advanced Hepatocellular Carcinoma. (Pubmed Central) - Jul 11, 2020
Combined lenvatinib/anti-PD-1 treatment appears to exert antitumor activity by synergistically modulating effector T cell function in the TME and by mutually regulating tumor vessel normalization. No abstract available
- ||||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Biomarker, FDA event, PD(L)-1 Biomarker, IO Biomarker: FDA Denies Approval of Pembrolizumab/Lenvatinib for Frontline Unresectable HCC | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. Am I reading (interpreting) this right?? Does this mean no more “ME TOO “ studies??!! https://t.co/t5W9tOM9Un (Twitter) - Jul 10, 2020
- | Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal: Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. (Pubmed Central) - Jul 9, 2020
Lenvatinib was effective for patients who did not meet the REFLECT inclusion criteria. However, the treatment outcome may vary according to several factors, such as a history of TKI treatment and tumor invasion.
- ||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
Enrollment open, Pan tumor: E7080-G000-231: A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) (clinicaltrials.gov) - Jul 8, 2020
P2, N=150, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
However, the treatment outcome may vary according to several factors, such as a history of TKI treatment and tumor invasion. Not yet recruiting --> Recruiting
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical, Journal: Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome. (Pubmed Central) - Jul 8, 2020
Not yet recruiting --> Recruiting A favorable middle-term outcome was obtained in patients with HCC receiving lenvatinib, especially in those manifesting grades 1/2a mALBI at baseline, despite the deterioration in ALBI scores during treatment.
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
FDA event: FDA Denies Approval of Pembrolizumab/Lenvatinib for Frontline Unresectable HCC https://t.co/EJDd4GUAgp via @targetedonc (Twitter) - Jul 8, 2020
- ||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
FDA event: Resposible decision by @US_FDA FDA Denies Approval of Pembrolizumab/Lenvatinib for Frontline Unresectable HCC https://t.co/4FvM9HNjmn via @targetedonc (Twitter) - Jul 8, 2020
- |||| Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Clinical: $MRK and Eisai Receive CRL for KEYTRUDA plus LENVIMA Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma (Twitter) - Jul 8, 2020
- || Keytruda (pembrolizumab) / Merck (MSD), Lenvima (lenvatinib) / Eisai, Merck (MSD)
Background to today's CRL for $MRK Keytruda + Lenvima in 1L liver cancer https://t.co/KJHqXfyaKI $RHHBY (Twitter) - Jul 8, 2020
- || Lenvima (lenvatinib) / Eisai, Merck (MSD)
Even if we start with lenvatinib 10, we titrate up to tolerance, in combinations (Twitter) - Jul 7, 2020